A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

PHASE2TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

January 10, 2022

Study Completion Date

February 18, 2022

Conditions
Neovascular Age-related Macular DegenerationRetinal DiseaseRetinal DegenerationMacular Degeneration
Interventions
BIOLOGICAL

GEM103

GEM103 500 mcg/50 mcL intravitreal injection

DRUG

Aflibercept

"Aflibercept 2 mg/50 mcL (SOC) intravitreal injection~Sham intravitreal injection"

DRUG

Sham

Sham intravitreal injection

Trial Locations (23)

21740

Gemini Clinical Trial Site 4, Hagerstown

28210

Gemini Clinical Trial Site 15, Charlotte

28803

Gemini Clinical Trial Site 2, Asheville

29902

Gemini Clinical Trial Site 13, Beaufort

33143

Gemini Clinical Trial Site 5, Miami

33782

Gemini Clinical Trial Site 7, Pinellas Park

33880

Gemini Clinical Trial Site 18, Winter Haven

34239

Gemini Clinical Trial Site 20, Sarasota

34994

Gemini Clinical Trial Site 8, Stuart

45219

Gemini Clinical Trial Site 6, Cincinnati

46290

Gemini Clinical Trial Site 19, Indianapolis

48073

Gemini Clinical Trial Site 22, Royal Oak

75231

Gemini Clinical Trial Site 3, Dallas

78240

Gemini Clinical Trial Site 21, San Antonio

78247

Gemini Clinical Trial Site 14, San Antonio

85021

Gemini Clinical Trial Site 16, Phoenix

89502

Gemini Clinical Trial Site 1, Reno

91107

Gemini Clinical Trial Site 12, Pasadena

91436

Gemini Clinical Trial Site 9, Encino

92647

Gemini Clinical Trial Site 17, Huntington Beach

95008

Gemini Clinical Trial Site 11, Campbell

97401

Gemini Clinical Trial Site 10, Eugene

01605

Gemini Clinical Trial Site 23, Worcester

Sponsors
All Listed Sponsors
lead

Gemini Therapeutics, Inc.

INDUSTRY